Cellular immunity delimits adenoviral gene therapy strategies for the treatment of neoplastic diseases

被引：28

作者：

DeMatteo, RP ^{[1
]}

Yeh, H ^{[1
]}

Friscia, M ^{[1
]}

Caparrelli, D ^{[1
]}

Burke, C ^{[1
]}

Desai, N ^{[1
]}

Chu, G ^{[1
]}

Markmann, JF ^{[1
]}

Raper, SE ^{[1
]}

Barker, CF ^{[1
]}

机构：

[1] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA

来源：

ANNALS OF SURGICAL ONCOLOGY | 1999年 / 6卷 / 01期

关键词：

adenovirus; gene therapy; immune response; cancer;

D O I：

10.1007/s10434-999-0088-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Adenoviral gene therapy is a promising new approach for the treatment of neoplastic diseases. To design rational clinical trials and distinguish the effects of therapeutic transgene expression From those caused by viral infection alone, the immune response to the vector must be understood. In these experiments, we further define cellular immunity to recombinant adenovirus. Methods: The immune response to hepatic adenoviral gene transfer was studied in infected mice by depleting T cells with an anti-CD3 antibody, measuring splenocyte cytokine production, determining the impact of transgene expression on inflammation, and assessing Liver MHC protein expression. Results: The cellular immune response to recombinant adenovirus is (I) averted by T lymphocyte depletion, (2) marked by a T(H)1 response with increased IL-2 production, (3) directed against both the transgene product and viral proteins, and (4) associated with increased hepatocyte MHC Class I expression. Conclusions: It is necessary to take into consideration the constraints imposed by the immunogenicity of recombinant adenovirus and its transient transgene expression in the clinical application of adenoviral gene transfer for the treatment of cancer.

引用

页码：88 / 94

页数：7

共 30 条

[21] EVALUATION OF THE TRANSFER AND EXPRESSION IN MICE OF AN ENZYME-ENCODING GENE USING A HUMAN ADENOVIRUS VECTOR [J].

STRATFORDPERRICAUDET, LD ;

LEVRERO, M ;

CHASSE, JF ;

PERRICAUDET, M ;

BRIAND, P .

HUMAN GENE THERAPY, 1990, 1 (03) :241-256

[22] Liver-directed gene transfer in non-human primates [J].

Sullivan, DE ;

Dash, S ;

Du, H ;

Hiramatsu, N ;

Aydin, F ;

Kolls, J ;

Blanchard, J ;

Baskin, G ;

Gerber, MA .

HUMAN GENE THERAPY, 1997, 8 (10) :1195-1206

[23]

TAKAHASHI T, 1992, CANCER RES, V52, P2340

[24] STABLE DELIVERY OF PHYSIOLOGICAL LEVELS OF RECOMBINANT ERYTHROPOIETIN TO THE SYSTEMIC CIRCULATION BY INTRAMUSCULAR INJECTION OF REPLICATION-DEFECTIVE ADENOVIRUS [J].

TRIPATHY, SK ;

GOLDWASSER, E ;

LU, MM ;

BARR, E ;

LEIDEN, JM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (24) :11557-11561

[25] Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors [J].

Tripathy, SK ;

Black, HB ;

Goldwasser, E ;

Leiden, JM .

NATURE MEDICINE, 1996, 2 (05) :545-550

[26] Gene therapy - promises, problems and prospects [J].

Verma, IM ;

Somia, N .

NATURE, 1997, 389 (6648) :239-242

[27]

Weichselbaum Ralph R., 1997, Lancet (North American Edition), V349, P10

[28]

Yang Y, 1996, GENE THER, V3, P137

[29] CELLULAR-IMMUNITY TO VIRAL-ANTIGENS LIMITS E1-DELETED ADENOVIRUSES FOR GENE-THERAPY [J].

YANG, YP ;

NUNES, FA ;

BERENCSI, K ;

FURTH, EE ;

GONCZOL, E ;

WILSON, JM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) :4407-4411

[30] MHC CLASS I-RESTRICTED CYTOTOXIC T-LYMPHOCYTES TO VIRAL-ANTIGENS DESTROY HEPATOCYTES IN MICE INFECTED WITH E1-DELETED RECOMBINANT ADENOVIRUSES [J].

YANG, YP ;

ERTL, HCJ ;

WILSON, JM .

IMMUNITY, 1994, 1 (05) :433-442

← 1 2 3 →